Is Zepbound Better Than Ozempic? Different Drugs, Different Approvals, Different Costs

Written by Dr. Sheri Tomas. Updated November 5, 2026.

Zepbound and Ozempic treat different things, so whether Zepbound is better depends on what you need it for: Zepbound (tirzepatide) is FDA-approved for chronic weight management and for obstructive sleep apnea (OSA) in adults with obesity, while Ozempic (semaglutide) is approved for type 2 diabetes, where it also lowers the risk of heart attack, stroke and kidney decline in certain patients. For weight loss, tirzepatide has beaten semaglutide in two head-to-head trials. In SURMOUNT-5, people without diabetes lost 20.2% of their body weight on tirzepatide against 13.7% on semaglutide, but the semaglutide dose there was 2.4 mg, which is Wegovy's dose, not Ozempic's. In SURPASS-2, in people with type 2 diabetes, tirzepatide lowered blood sugar and weight more than Ozempic's 1 mg dose. This guide compares the two side by side and covers trials, side effects, label dosing, self-pay prices as of November 2026 and Medicare.

It depends on the goal. If the goal is weight loss in someone without diabetes, Zepbound is the drug that is actually approved for it, and tirzepatide produced more weight loss than semaglutide in the only head-to-head trial in that group. Ozempic is not an option on its label for weight loss alone; its approved uses are all in adults with type 2 diabetes, as we explain in is Ozempic approved for weight loss. If the goal is blood sugar control in type 2 diabetes, tirzepatide also did better in a head-to-head trial, but Zepbound is not labeled for diabetes. Lilly sells tirzepatide for diabetes under a different name, Mounjaro, compared in Ozempic vs Mounjaro. And Ozempic has proven heart and kidney benefits in type 2 diabetes that Zepbound's label does not include.

Zepbound contains tirzepatide, made by Eli Lilly. Ozempic contains semaglutide, made by Novo Nordisk. Both copy hormones the gut releases after a meal. Semaglutide is a GLP-1 receptor agonist: it switches on the receptor for GLP-1 (glucagon-like peptide-1), which helps the pancreas release insulin when blood sugar is high, slows stomach emptying and reduces appetite. A plain-English walk-through is in how Ozempic works. Tirzepatide is a dual GIP and GLP-1 receptor agonist: it also switches on the receptor for GIP (glucose-dependent insulinotropic polypeptide), a second gut hormone involved in insulin release. That dual action is the main difference between the molecules.

According to the Zepbound label revised in April 2026, Zepbound is approved, together with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off long term in adults with obesity, or with overweight plus at least one weight-related health problem. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity, an approval the FDA granted in December 2024. In February 2026 Lilly launched a multi-dose Zepbound KwikPen that holds four weekly doses.

According to the Ozempic label revised in May 2026, Ozempic is approved for adults with type 2 diabetes to improve blood sugar control alongside diet and exercise; to lower the risk of major cardiovascular events (heart attack, stroke or cardiovascular death) in those with established heart disease; and, since January 2025, to lower the risk of sustained kidney function decline, kidney failure and cardiovascular death in those with chronic kidney disease. It has no weight-management indication. Semaglutide for weight loss is sold as Wegovy, covered in Ozempic vs Wegovy.

Yes, twice, and both trials were funded by Lilly, the maker of tirzepatide. SURPASS-2, published in the New England Journal of Medicine in 2021, compared three tirzepatide doses with semaglutide 1 mg, one of Ozempic's doses, in 1,879 adults with type 2 diabetes over 40 weeks. SURMOUNT-5, published in the same journal in 2025, compared the highest tolerated dose of tirzepatide (10 or 15 mg) with the highest tolerated dose of semaglutide (1.7 or 2.4 mg) in 751 adults with obesity but no diabetes over 72 weeks.

Tirzepatide did in both trials. In SURMOUNT-5, average weight loss at 72 weeks was 20.2% with tirzepatide and 13.7% with semaglutide. At the European Congress on Obesity in May 2025, investigators reported that 81.6% of people on tirzepatide lost at least 10% of their weight, against 60.5% on semaglutide, and 31.6% lost at least 25%, against 16.1%.

Here is the point many comparisons blur: SURMOUNT-5 did not test Ozempic. The semaglutide arm used up to 2.4 mg, which is Wegovy's weight-loss dose. Ozempic's highest dose is 2 mg, and it is labeled for diabetes. So the 20.2% versus 13.7% result is a comparison of Zepbound-level tirzepatide with Wegovy-level semaglutide. The trial that did use an Ozempic dose is SURPASS-2, where weight loss was 8.5% to 13.1% with tirzepatide against 6.7% with semaglutide 1 mg in people with type 2 diabetes.

For someone whose main goal is weight loss and who does not have type 2 diabetes, Zepbound is the labeled option and the one with stronger head-to-head results. Novo Nordisk's self-pay program requires an Ozempic prescription for a labeled indication, and Medicare does not cover it for weight loss. For someone with type 2 diabetes who also wants to lose weight, the choice is usually between Ozempic and Mounjaro (tirzepatide's diabetes brand), and heart or kidney disease may tip it toward Ozempic because of its outcome-trial approvals. Other options are compared in Ozempic alternatives compared.

Both drugs mainly cause stomach and gut side effects, which are most common while the dose is being raised. The labels report different trials, so rates are not directly comparable. In Zepbound's weight-management trials, nausea affected 25% to 29% of people across the 5, 10 and 15 mg doses (8% on placebo), diarrhea 19% to 23%, vomiting 8% to 13% and constipation 11% to 17%; 4.8% to 6.7% stopped because of side effects, against 3.4% on placebo. In Ozempic's diabetes trials, nausea affected 15.8% on 0.5 mg and 20.3% on 1 mg (6.1% on placebo), diarrhea about 8.5% to 8.8% and vomiting 5% to 9.2%; 3.1% to 3.8% stopped because of gut side effects.

The head-to-head trials are a fairer comparison. In SURPASS-2, nausea was similar: 17.4% to 22.1% on tirzepatide and 17.9% on semaglutide 1 mg. In SURMOUNT-5, fewer people stopped tirzepatide for gut side effects (2.7%) than semaglutide (5.6%). Both labels carry the same boxed warning: the drugs caused thyroid C-cell tumors in rats, it is not known whether they do in people, and neither should be used by anyone with a personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN 2). Tips for one common problem are in Ozempic diarrhea.

Label information only; your prescriber sets your schedule. Zepbound starts at 2.5 mg once a week for 4 weeks. The dose then goes to 5 mg and can rise in 2.5 mg steps after at least 4 weeks on each dose. Maintenance doses are 5, 10 or 15 mg for weight management and 10 or 15 mg for sleep apnea, with a maximum of 15 mg. Ozempic starts at 0.25 mg once a week for 4 weeks, then 0.5 mg; maintenance doses are 0.5, 1 or 2 mg, with at least 4 weeks between increases, and 1 mg for chronic kidney disease.

On LillyDirect (page dated September 2, 2026), Zepbound KwikPen or vials cost $299 for 28 days at 2.5 mg and $399 at 5 mg. The 7.5 to 15 mg doses cost $449 if you refill within 45 days; otherwise the price is $499 for 7.5 mg and $699 for 10 to 15 mg. The single-dose pen is available only through insurance. Lilly cut these self-pay prices on December 1, 2025.

Through NovoCare, Ozempic costs $349 a month for the 0.25, 0.5 and 1 mg doses and $499 for 2 mg. New patients can pay $199 for their first two fills of 0.25 or 0.5 mg if the prescription is written by December 31, 2026. The program requires that Ozempic be prescribed for a labeled indication, which in practice means type 2 diabetes. More detail is in how much Ozempic costs per month in 2026.

Commercial coverage varies by plan; see does insurance cover Ozempic. Medicare Part D can cover Ozempic for type 2 diabetes and chronic kidney disease, but not for weight loss, because a 2003 law bars standard Part D from covering anti-obesity drugs. From July 1, 2026 to December 31, 2027, the Medicare GLP-1 Bridge offers certain weight-loss drugs for a $50 copay. It covers Wegovy, Foundayo and the Zepbound KwikPen only, not Zepbound vials or single-dose pens, and not Ozempic. To qualify you need a BMI of 35 or more; or 30 or more with heart failure with preserved ejection fraction, uncontrolled high blood pressure or stage 3a or worse kidney disease; or 27 or more with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. People whose qualifying diagnosis is type 2 diabetes, sleep apnea or MASH (a fatty liver disease) are excluded from the Bridge.

Switching is a prescriber's decision. The Zepbound label says it should not be used together with other tirzepatide products or with any GLP-1 receptor agonist, which includes Ozempic, so the two are not taken at the same time. Neither label gives a conversion chart between the drugs, and the milligram doses do not line up. Zepbound is not labeled for diabetes, and coverage may differ.

If you are just starting the process, see how to get prescribed Ozempic, and for diabetes-specific use, Ozempic for diabetes.

Zepbound and Ozempic are different drugs with different approvals. Zepbound is the one approved for weight management and sleep apnea, and tirzepatide caused more weight loss than semaglutide in head-to-head trials, though the big SURMOUNT-5 result was against Wegovy's dose, not Ozempic's. Ozempic is a type 2 diabetes drug with proven heart and kidney benefits and no weight-loss approval. As of November 2026, Zepbound costs $299 to $449 per 28 days self-pay with timely refills and Ozempic $349 to $499 a month, and only the Zepbound KwikPen is part of Medicare's $50 Bridge. The right choice depends on your diagnosis, health history and coverage.

This article summarizes drug labels and published research for general information and is not medical advice. Both head-to-head trials (SURPASS-2 and SURMOUNT-5) were funded by Eli Lilly, the maker of tirzepatide.